16 May 2025 : Clinical Research
Impact of Sitagliptin on Neprilysin and Glycemic Control in Newly Diagnosed Type 2 Diabetes Patients
Cuma Bulent Gül ABCDEF 1*, Aysegul Oruc CDF 1, Soner Cander ABF 1, Ensar Aydemir
BF 2, Ozen Oz Gül ABCDEFG 1
DOI: 10.12659/MSM.949107
Med Sci Monit 2025; 31:e949107
Table 1 Changes in the anthropometric measurements between the beginning and 3rd month of the treatment.
| Parameter | BaselineMean±SD (n=35) | 3rd MonthMean±SD (n=35) | p-value |
|---|---|---|---|
| Weight (kg) | 86.10±15.26 | 84.44±14.58 | |
| BMI (kg/m) | 32.30±5.80 | 31.68±5.60 | |
| Waist circumference (cm) | 106.53±13.97 | 104.87±13.52 | 0.067 |
| Fat percentage (%) | 34.84±8.44 | 34.10±8.97 | 0.138 |
| Systolic blood pressure (mmHg) | 124.12±9.57 | 125.88±8.57 | 0.157 |
| Diastolic blood pressure (mmHg) | 77.50±8.00 | 79.12±7.93 | 0.351 |
| BMI – body mass index; SD – standard deviation. | |||